Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000050161 | SCV004297176 | likely pathogenic | Imerslund-Grasbeck syndrome | 2023-11-10 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the AMN gene (p.His438Glnfs*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 16 amino acid(s) of the AMN protein and extend the protein by an uncertain number of additional amino acid residues. This variant is present in population databases (rs767203418, gnomAD 0.008%). This frameshift has been observed in individual(s) with Imerslund-GraÃàsbeck syndrome (PMID: 22929189). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56748). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000050161 | SCV000082571 | probable-pathogenic | Imerslund-Grasbeck syndrome | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |